Quick access to main page (top) Direct access to main contents Quick access to main page (bottom)

Neurocrine’s New CAH Drug, Krenicity, Gets FDA Approval—Here’s What You Need to Know

Daniel Kim Views  

Neurocrine Biosciences\' treatment for the rare genetic disorder CAH has received FDA approval in the United States
Medical Today DB

In a significant advancement for rare disease treatment, the U.S. Food and Drug Administration (FDA) has approved Neurocrine Biosciences’ new therapy for congenital adrenal hyperplasia (CAH).

The FDA recently approved Krenicity, a novel therapy by Neurocrine Biosciences designed specifically for typical CAH. This approval represents a pivotal milestone in the management of this rare condition.

CAH is a rare inherited disorder that affects the adrenal glands. These glands produce essential hormones such as cortisol and androgens. Patients with CAH often fail to produce sufficient cortisol, which is critical for stress regulation, while overproducing androgen hormones similar to testosterone.

To compensate for these hormonal imbalances, CAH patients typically rely on higher-than-normal doses of glucocorticoids to supplement cortisol deficiency and suppress excessive androgen production.

The FDA has approved Krenicity for adults and children aged 4 and older with CAH to be used alongside standard glucocorticoid therapy. A Neurocrine spokesperson stated that Krenicity will become commercially available within a week.

Krenicity’s mechanism of action involves reducing the overproduction of androgens, which in turn allows for lower glucocorticoid dosage requirements.

Neurocrine’s clinical trials showed promising results. In a 24-week study involving 122 adult CAH patients, those treated with Krenicity twice daily successfully reduced their daily glucocorticoid dose by up to 27% while maintaining stable levels of androstenedione, a key androgen hormone. These outcomes contrasted with those of the 60 patients who received a placebo.

The drug demonstrated similar efficacy in pediatric patients. In a 28-week trial involving 69 children with CAH, participants treated with Krenicity twice daily maintained stable hormone levels despite reducing their daily glucocorticoid dose by 18%, compared to the placebo group.

Daniel Kim
content@viewusglobal.com

Comments0

300

Comments0

[LIFESTYLE] Latest Stories

  • How Apples Can Help You Lose Weight and Stay Healthy
  • How Sitting Too Long Is Impacting Adults' Health and Well-being
  • Grilled Food and Cancer Risk: How Harmful Is the Smoke?
  • Is Your Workout Routine Effective? Watch for These Red Flags
  • BMW Z8 Surfaces at Auction: A Rare V8 Roadster with Only 7,000 Miles
  • Microplastics Found to Raise Risk of Cognitive Decline, Mental Disorders

You May Also Like

  • 1
    Land Cruiser 300 Revamp Set for March 18, But Delivery Delays Persist

    BUSINESS 

  • 2
    BMW Launches 330Li Long Wheelbase Model in India with Enhanced Interior Space

    BUSINESS 

  • 3
    Porsche Enhances Battery Production Capabilities with Acquisition of V4Drive

    BUSINESS 

  • 4
    Tesla’s Stock Struggles in 2025, as Musk Offers Cautious Outlook on Growth

    BUSINESS 

  • 5
    Kia’s EV3: A New Approach to Pricing or Just a Price Hike in Disguise?

    BUSINESS 

Popular Now

  • 1
    Palisade or Explorer? Comparing Two Powerhouses in the Large SUV Market

    BUSINESS 

  • 2
    BMW Outpaces Mercedes-Benz, Tesla Model Y Dominates February Sales

    BUSINESS 

  • 3
    Hyundai IONIQ 5 N Line Beats Volkswagen ID.4 GTX in Key European EV Face-Off

    BUSINESS 

  • 4
    Kia EV8 to Revive Stinger Spirit with 600+ HP and 500-Mile Range

    BUSINESS 

  • 5
    BYD Confident in EV Market Growth, Willing to Share Tech with Tesla and Others

    BUSINESS 

Must-Reads

  • 1
    Land Cruiser 300 Revamp Set for March 18, But Delivery Delays Persist

    BUSINESS 

  • 2
    BMW Launches 330Li Long Wheelbase Model in India with Enhanced Interior Space

    BUSINESS 

  • 3
    Porsche Enhances Battery Production Capabilities with Acquisition of V4Drive

    BUSINESS 

  • 4
    Tesla’s Stock Struggles in 2025, as Musk Offers Cautious Outlook on Growth

    BUSINESS 

  • 5
    Kia’s EV3: A New Approach to Pricing or Just a Price Hike in Disguise?

    BUSINESS 

Popular Now

  • 1
    Palisade or Explorer? Comparing Two Powerhouses in the Large SUV Market

    BUSINESS 

  • 2
    BMW Outpaces Mercedes-Benz, Tesla Model Y Dominates February Sales

    BUSINESS 

  • 3
    Hyundai IONIQ 5 N Line Beats Volkswagen ID.4 GTX in Key European EV Face-Off

    BUSINESS 

  • 4
    Kia EV8 to Revive Stinger Spirit with 600+ HP and 500-Mile Range

    BUSINESS 

  • 5
    BYD Confident in EV Market Growth, Willing to Share Tech with Tesla and Others

    BUSINESS 

Share it on...